Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The natural history and treatment outcome of blast phase BCR-ABL- myeloproliferative neoplasms.

Blood - 1 Sept 2008

Tam Constantine S, Nussenzveig Roberto M, Popat Uday, Bueso-Ramos Carlos E, Thomas Deborah A, Cortes Jorge A, Champlin Richard E, Ciurea Stefan E, Manshouri Taghi, Pierce Sherry M, Kantarjian Hagop M, Verstovsek Srdan

Abstract excerpt

We analyzed the outcomes of 74 patients diagnosed with BCR-ABL(-) myeloproliferative neoplasms in blast phase receiving induction chemotherapy (55%), low-intensity therapy (16%), stem cell transplantation (SCT; 3%), or supportive care (26%). Median survival from the date of blastic transformation was 5 months. Patients receiving supportive therapy had a median survival of 6 weeks. Complete remission with or...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Blast Crisis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genes, abl

Share to Janus Kinase 2

Share to Leukemia, Myeloid, Acute

Share to Myeloproliferative Disorders

Share to Stem Cell Transplantation

Share to Survival Rate

Source

Open in PubMed Open full text

Identifiers

PMID: 18566326
DOI: 10.1182/blood-2008-02-138230
PMCID: PMC2518875

Genes

SCT
BCR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The natural history and treatment outcome of blast phase BCR-ABL- myeloproliferative neoplasms.PMID 18566326Read ↗

Outcomes and predictors of survival in blast phase myeloproliferative neoplasms.Semantic proximity Read ↗

Updates on accelerated and blast phase myeloproliferative neoplasms: Are we making progress?Semantic proximity Read ↗

A Concise Update on Risk Factors, Therapy, and Outcome of Leukemic Transformation of Myeloproliferative Neoplasms.Semantic proximity Read ↗

Blast Phase of Myeloproliferative Neoplasm Resembles Acute Myeloid Leukemia, Myelodysplasia-Related, in Clinical Presentation, Cytogenetic Pattern, and Genomic Profile, and Often Undergoes Reversion to Second Chronic Phase Status After Induction Chemotherapy.Semantic proximity Read ↗

Blast phase myeloproliferative neoplasm: contemporary review and 2024 treatment algorithm.Semantic proximity Read ↗

Transformation of a chronic myeloproliferative neoplasm to acute myelogenous leukemia: does anything work?Semantic proximity Read ↗

Pathobiology of lymphoid and myeloid blast crisis and management issues.Semantic proximity Read ↗

Management and Outcomes of Blast Transformed Chronic Myelomonocytic Leukemia.Semantic proximity Read ↗

Targeted next-generation sequencing in blast phase myeloproliferative neoplasms.Semantic proximity Read ↗

The Biology of CML blast crisis.Semantic proximity Read ↗

Prognostic Factors and Clinical Outcomes in Patients with Blast Phase Chronic Myeloid Leukemia.Semantic proximity Read ↗

Chronic myeloid leukemia: mechanisms of blastic transformationSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.